In the last years, significant advances have improved the knowledge of myasthenia gravis (MG) immunopathogenesis and have enabled to realize new molecules with a selective action targeting compounds of the immunological system. This review discusses emerging treatments for MG, including complement inhibitors, neonatal Fc receptor targeting agents, and B cell interfering drugs, focusing on benefit and danger. In the second section of the review, several related adverse events of immunotherapy, including MGonset, are debated.
Benefit and danger from immunotherapy in myasthenia gravis / Rodolico C.; Nicocia G.; Damato V.; Antonini G.; Liguori R.; Evoli A.. - In: NEUROLOGICAL SCIENCES. - ISSN 1590-1874. - ELETTRONICO. - 42:(2021), pp. 1367-1375. [10.1007/s10072-021-05077-6]
Benefit and danger from immunotherapy in myasthenia gravis
Damato V.;
2021
Abstract
In the last years, significant advances have improved the knowledge of myasthenia gravis (MG) immunopathogenesis and have enabled to realize new molecules with a selective action targeting compounds of the immunological system. This review discusses emerging treatments for MG, including complement inhibitors, neonatal Fc receptor targeting agents, and B cell interfering drugs, focusing on benefit and danger. In the second section of the review, several related adverse events of immunotherapy, including MGonset, are debated.
| File | Dimensione | Formato | |
|---|---|---|---|
|
Benefit and danger from immunotherapy in myasthenia gravis.pdf
Open Access dal 01/01/2023
Tipologia:
Versione finale referata (Postprint, Accepted manuscript)
Licenza:
Solo lettura
Dimensione
597.14 kB
Formato
Adobe PDF
|
597.14 kB | Adobe PDF | |
|
10072_2021_Article_5077.pdf
Accesso chiuso
Tipologia:
Pdf editoriale (Version of record)
Licenza:
Tutti i diritti riservati
Dimensione
704.51 kB
Formato
Adobe PDF
|
704.51 kB | Adobe PDF | Richiedi una copia |
I documenti in FLORE sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
